Herein, we perform a comprehensive analysis of grade 2 meningiomas, assessing their global DNA methylation profiles and telomerase reverse transcriptase (TERT) promoter mutation status, determining their molecular risk group, and correlating this to the clinical course with subsequent analysis of treatment decision-making. The gene discussed is TERT; the disease is meningioma.